Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD) ; volume:28 ; number:3 ; day:24 ; month:3 ; year:2009 ; pages:260-267 ; date:6.2010
Investigational new drugs ; 28, Heft 3 (24.3.2009), 260-267, 6.2010
- Urheber
-
O’Donnell, Robert T.
Martin, Shiloh M.
Ma, Yunpeng
Zamboni, William C.
Tuscano, Joseph M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-009-9243-7
- URN
-
urn:nbn:de:101:1-2019100914244208928220
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- O’Donnell, Robert T.
- Martin, Shiloh M.
- Ma, Yunpeng
- Zamboni, William C.
- Tuscano, Joseph M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer